Cargando…

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

PURPOSE: Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and azacitidine (AZA) possess significant antitumor a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Craddock, Charles, Slade, Daniel, De Santo, Carmela, Wheat, Rachel, Ferguson, Paul, Hodgkinson, Andrea, Brock, Kristian, Cavenagh, Jamie, Ingram, Wendy, Dennis, Mike, Malladi, Ram, Siddique, Shamyla, Mussai, Francis, Yap, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494237/ https://www.ncbi.nlm.nih.gov/pubmed/30653424 http://dx.doi.org/10.1200/JCO.18.00889

Ejemplares similares

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
por: Craddock, Charles, et al.
Publicado: (2016)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
por: Feng, Yimei, et al.
Publicado: (2023)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Implementing the EffTox dose-finding design in the Matchpoint trial
por: Brock, Kristian, et al.
Publicado: (2017)

Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges
por: Yap, Christina, et al.
Publicado: (2013)

Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation
por: Sumi, Masahiko, et al.
Publicado: (2020)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report
por: Mekni, Sabrine, et al.
Publicado: (2023)

Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report
por: Garcia-Recio, Marta, et al.
Publicado: (2016)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia
por: Mussai, Francis, et al.
Publicado: (2019)

Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
por: Guglielmelli, Tommasina, et al.
Publicado: (2009)

Azacitidine as Salvage Therapy for Acute Myeloid Leukemia in a Severely Ill Patient
por: Powers, Harry Ross, et al.
Publicado: (2014)

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
por: Loke, Justin, et al.
Publicado: (2019)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
por: Horvat, Nathan P, et al.
Publicado: (2022)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
por: Stadtmauer, Edward A, et al.
Publicado: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
por: Follo, Matilde Y., et al.
Publicado: (2019)

Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report
por: Keino, Dai, et al.
Publicado: (2019)

A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2019)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
por: Mongiorgi, Sara, et al.
Publicado: (2023)

Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment
por: Ma, Li-Yangxue, et al.
Publicado: (2018)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
por: Cheung, Verna, et al.
Publicado: (2022)

ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant
por: Horgan, Claire, et al.
Publicado: (2020)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies
por: Fultang, Livingstone, et al.
Publicado: (2021)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, Vasiliki, et al.
Publicado: (2022)

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
por: Hunault-Berger, M, et al.
Publicado: (2017)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
por: Falconi, Giulia, et al.
Publicado: (2018)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ujva0594ljqlvpi65bp9i3d8k9